Table 3.
Risk factors for HBV reactivation.
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Rejection | 2.731 (0.653, 11.429) | 0.169 | ||
| Use of ATG | 1.509 (0.183, 12.429) | 0.702 | ||
| Standard dose rituximab | 8.256 (1.973, 34.551) | 0.004 | 10.598 (2.519, 44.599) | 0.001 |
| anti-HBs ≥ 100 IU/L | 0.149 (0.018, 1.214) | 0.075 | 0.11 (0.013, 0.905) | 0.04 |
| Donor anti-HBc (+) | 0.652 (0.132, 3.230) | 0.600 | ||
| Causes of rituximab | 0.885 (0.148, 5.297) | 0.893 | ||
| Number of plasmapheresis | 1.343 (0.862, 1.913) | 0.314 | ||
| Tacrolimus trough level | 0.899 (0.652, 1.240) | 0.516 | ||
| MMF dose | 1.001 (0.999,1.002) | 0.280 | ||